FDA Mandates Blindness Warning for Ozempic and All GLP-1 Drugs Due to NAION Risk
The U.S. Food and Drug Administration (FDA) has issued a new requirement for Ozempic, Wegovy, Mounjaro, Zepbound, and all other GLP-1 class drugs to carry a warning about Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). NAION is a rare but serious optic nerve injury that can lead to permanent vision loss in one eye. This decision follows an FDA review of 126 clinical trials, which indicated a higher rate of NAION among GLP-1 users compared to patients receiving other treatments. The FDA's analysis of pooled data from these trials found 15 probable NAION cases, with two-thirds (10 cases) occurring in patients on a GLP-1 drug. Furthermore, an analysis using the Sentinel system, which tracks medical and insurance records, revealed that GLP-1 users had a 43% higher risk of NAION than patients taking DPP-4 inhibitors, another class of diabetes medication. The warning applies to all GLP-1 drugs, regardless of whether they are prescribed for diabetes, weight loss, or cardiovascular risk reduction. Patien...